In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
News|Podcasts|August 19, 2026
ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine which Phase I administrative processes are most ripe for AI automation, how sponsors should balance investor demands for real-time data against scientific rigor in capital-constrained trials, and a major CRO's expanded artificial intelligence partnerships.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part two of her interview , Amber Hill, PhD, founder and CEO of Research Grid, identified the administrative back-office processes causing the most friction in Phase I trials. Purpose-built, traceable AI models designed for regulatory environments are the right tool for addressing them, with the biggest early wins in scheduling, protocol compliance monitoring, and data reconciliation. - In a
new contributed article , Deborah Phippard, PhD, chief scientific officer of Precision for Medicine, addressed how sponsors can build lean but robust early-phase evidence packages when investors demand patient-level data as it emerges. Without biological context, two responders and two nonresponders do not establish a trend, and biobanked samples retained prospectively allow teams to investigate outliers or rescue ambiguous datasets at modest incremental cost. Syneos Health announced three AI platform partnerships expanding its clinical development capabilities, including integrations with Causaly for evidence-based protocol strategy, Databricks for near-real-time operational data reducing source-to-insight time from days to hours, and Microsoft for workflow automation. Together, the partnerships are designed to create a unified intelligence environment connecting operational, clinical, and real-world data across the development lifecycle.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Syneos Health, Optum Partner on Adaptive Clinical Development Model
4
ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit
5